0 69

Cited 0 times in

Depressive Symptoms in Stroke Patients: Are There Sex Differences?

 Eun-Jae Lee  ;  Jong S Kim  ;  Dae-Il Chang  ;  Jong-Ho Park  ;  Seong Hwan Ahn  ;  Jae-Kwan Cha  ;  Ji Hoe Heo  ;  Sung-Il Sohn  ;  Byung-Chul Lee  ;  Dong-Eog Kim 10  ;  Hahn Young Kim 11  ;  Seongheon Kim 12  ;  Do-Young Kwon 13  ;  Jei Kim 14  ;  Woo-Keun Seo 15  ;  Jun Lee 16  ;  Sang-Won Park 17  ;  Seong-Ho Koh 18  ;  Jin Young Kim 19  ;  Smi Choi-Kwon 20 
 CEREBROVASCULAR DISEASES, Vol.49(1) : 19-25, 2020-02 
Journal Title
Issue Date
Depression ; Sex ; Stroke
Background: We aimed to examine sex differences in symptom characteristics and pharmacological responses in post-stroke depressive (PSD) symptoms. Methods: This is a post hoc analysis of EMOTION (ClinicalTrials.gov, NCT01278498), a randomized, placebo-controlled, double-blind trial that examined the efficacy of escitalopram for 3 months on depression in patients with acute stroke. Depressive symptoms were evaluated using the 10-item Montgomery-Åsberg Depression Rating Scale (MADRS). Baseline characteristics, clinical variables, and treatment responses to escitalopram were compared between male and female patients. Treatment responses were defined as changes in MADRS (total score and its components) between baseline and 3 months and were compared between the escitalopram and placebo groups within each sex group. The least square mean was calculated to determine the independent effect of escitalopram, of which interaction was evaluated with patient sex. Results: Of the 478 patients (intention-to-treat population), 187 (39%) were female. Female patients were significantly older than male patients and demonstrated more severe depressive symptoms at baseline (male vs. female, MADRS score, mean [SD]: 9.7 ± 8.0 vs. 12.2 ± 8.4, p = 0.001), especially in apparent sadness, reported sadness, and reduced appetite items. These differences were significant after adjustment for age and the severity of neurologic deficits. The female escitalopram group showed a significant 3-month improvement in MADRS scores (placebo [n = 86] vs. escitalopram [n = 101], least square mean [95% CI] -2.7 [-4.1 to -1.2] vs. -5.0 [-6.4 to -3.6], p = 0.007), and this efficacy was prominent in apparent sadness, reported sadness, and pessimistic thoughts items. However, there was no significant effect of escitalopram on depressive symptoms in the male group. The treatment responses of escitalopram tended to be more pronounced in the female group, particularly in alleviating a subset of depressive symptoms such as apparent sadness (p for interaction = 0.009). Conclusion: PSD may differ according to sex in its symptom characteristics and treatment responses to escitalopram, and tailored treatment strategies for PSD may therefore be needed.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Heo, Ji Hoe(허지회) ORCID logo https://orcid.org/0000-0001-9898-3321
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.